LIGAND PHARMACEUTICALS INC
For the period ended Mar 31, 2026. Filed May 8, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 8, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 5. Other Information
Rule 10b5-1 Trading Arrangements
From time to time, our officers (as defined in Rule 16a-1(f) of the Exchange Act) and directors may enter into Rule 10b5-1 or non-Rule 10b5-1 trading arrangements (as each such term is defined in Item 408 of Regulation S-K).
During the quarter ended March 31, 2026, Octavio Espinoza, our Chief Financial Officer, modified a Rule 10b5‑1 trading arrangement that had been adopted on November 19, 2025. The modification, effected on February 19, 2026, removed an award that had been inadvertently included in the trading arrangement at the time of adoption. No other terms of the trading arrangement were changed.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.